Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers

Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That view seems conservative. Here's why.

from Health and Science https://ift.tt/QyzGOlP
https://ift.tt/3NnMody
https://ift.tt/0ADvPen